U.S. Transdermal Drug Delivery System Market (2023 - 2030)

Report Overview

The U.S. transdermal drug delivery system market size was valued at USD 30.31 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 11.4% from 2023 to 2030. Increasing demand for painless drug delivery, coupled with rising demand for self-administration of drugs, is anticipated to fuel the growth. The growth of the market is also propelled by ongoing technological advancements in the field.

The COVID-19 pandemic ushered in mask mandates, quarantines, product shortages, business closures, and businesses scrambling to figure out new ways to keep their doors open. The pandemic had a huge negative impact on the U.S., with the country reporting the highest number of COVID-19 cases for a majority of the time over the two years of the pandemic. Therefore, the U.S. transdermal drug delivery system market observed a significant drop in sales as well. Reduced number of patients visiting healthcare facilities and a large number of people opting to quarantine themselves as a precautionary measure resulted in a drop in sales.

However, the pandemic highlighted many loopholes in the healthcare system and the country is now working toward them to avoid such circumstances in the future. Moreover, with everything returning to normalcy and the U.S. government now, more than ever, focusing on the healthcare sector, the market is expected to flourish at a rapid pace.

The transdermal drug delivery system represents the most attractive method among various recently emerged non-invasive administrations as an alternative to conventional needle injections. This is because of its excellent ease of administration, low rejection rate, excellent convenience, and persistence among patients. It can be applicable in pharmaceuticals as well as the skin care industry, including cosmetics. This makes it an ideal option for the non-invasive administration of drugs and in turn, drives the demand for these systems.

The high prevalence of chronic disorders is anticipated to fuel the market for transdermal drug delivery systems. Cardiovascular disorders, Alzheimer’s disease, and diabetes are some of the leading chronic conditions affecting U.S. citizens. These conditions require round-the-clock monitoring and frequent dose administration, thus facilitating the market growth. For instance, according to the American Diabetes Association, about 37.2 million people in the U.S. had diabetes in 2019.

Transdermal drug delivery systems represent a great potential to administer insulin non-invasively. Microneedles used for transdermal delivery can improve patient compliance and patients can self-administer it. Therefore, it signifies great potential as an alternative to traditional insulin therapy. Thus, increasing preference for therapies that can be self-administered is also a major factor boosting the demand for transdermal drug delivery systems.

Technology Insights

The iontophoresis segment dominated the market in 2022 owing to technological advancements. Moreover, this technology has many advantages such as avoidance of first-pass metabolism for systemic administration, as well as faster administration and better control of the delivered dose in comparison to the usual passive transdermal formulations.

The mechanical arrays segment is anticipated to progress at a lucrative CAGR of over 12.7% throughout the forecast period. An increasing number of product launches by prominent industry players and increasing adoption of micro-needling in aesthetics exemplify the high growth potential possessed by this segment. For instance, in June 2021, Eclipse received FDA approval for its latest medical-grade micro-needling device, the MicroPen EVO. The product was launched in Canada last year and has been available to dermatologists and aesthetic practitioners in the U.S. since June 2021.

Application Insights

The pain management segment held the highest share of 22.7% in 2022. This is due to the increasing prevalence of chronic diseases and trauma. The growing prevalence of musculoskeletal disorders such as arthritis, osteoarthritis, and orthopedic degenerative disorders is also contributing to a rise in the prevalence of chronic pain. According to Osteoarthritis Action Alliance, in 2022, an estimated 32.5 million people are affected by osteoarthritis in the U.S.

The CNS segment held the second largest share owing to the growing burden of neurological disorders such as Alzheimer’s. According to the Alzheimer’s Association, an estimated 6.5 million people aged 65 and over are living with Alzheimer’s in the U.S. as of 2022. This is further projected to grow up to 12.7 million by the end of 2050.

The cardiovascular segment is anticipated to undergo maximum growth over the forecast period. Increasing utilization of transdermal drug delivery systems in the treatment of hypertension, congestive heart failures, and angina pectoris is majorly driving the growth of the cardiovascular segment. For instance, the advent of nitroglycerin, clonidine, and isosorbide dinitrate transdermal systems, used in the treatment of hypertension, have proven to be highly efficacious in treating complicated as well as uncomplicated treatment phases.

Key Companies & Market Share Insights

Mergers and acquisitions form one of the key sustainable strategies undertaken by market players. For instance, in June 2022, Novartis AG acquired Kedalion therapeutics, a U.S.-based company, to strengthen its drug delivery business. Through this acquisition, the company aims to enhance the delivery and patient experience with its medicines.

In addition, Nutriband Inc. completed the acquisition of Pocono Coated Product's Transdermal and Health product manufacturing business. The company aims to expand its business and advance its in-house manufacturing capabilities to become a leading player in the transdermal drug delivery system market. Some prominent players in the U.S. transdermal drug delivery system market include:

• Novartis AG

• Johnson & Johnson

• Viatris Inc.

• Boehringer Ingelheim GmbH

• Biogel Technology, Inc.

• 3M Company

• Noven Pharmaceuticals, Inc.

• Nutriband Inc.

• Transdermal Corporation

• Echo Therapeutics, Inc.

U.S. Transdermal Drug Delivery System Market